Replies to post #9619 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Peter, given that Gleevec has shown little benefit for high risk pts (Nature 2005), I think your view that this patient population represents the best opportunity to move ponatnib to 1st line is right on the mark. Using Sokal criteria, this could represent anywhere from 10% to 18% of newly diagnosed CML pts in the US and up to 30% of pts internationally. (see "Risk Stratification of Patients of Chronic Myeloid Leukemia According to Sokal Criteria")

btw, do you know of any trials that have been run comparing tasigna or sprycel to gleevec in high risk pts?

[rkrw]

Another EGFR T790 player.

http://www.avilatx.com/pipeline/egfr-mutant-selective-inhibitor-program.html